Danaher Co. (NYSE:DHR) Shares Bought by Cypress Capital Group

Cypress Capital Group grew its position in Danaher Co. (NYSE:DHR) by 1.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,885 shares of the conglomerate’s stock after buying an additional 75 shares during the quarter. Cypress Capital Group’s holdings in Danaher were worth $1,221,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of DHR. GUNN & Co INVESTMENT MANAGEMENT INC. acquired a new position in Danaher during the 4th quarter worth $306,000. South Dakota Investment Council lifted its holdings in Danaher by 82.4% during the 4th quarter. South Dakota Investment Council now owns 11,995 shares of the conglomerate’s stock worth $2,775,000 after buying an additional 5,420 shares during the last quarter. Capital Advisors Ltd. LLC lifted its holdings in Danaher by 6.5% during the 4th quarter. Capital Advisors Ltd. LLC now owns 1,844 shares of the conglomerate’s stock worth $427,000 after buying an additional 112 shares during the last quarter. Atria Wealth Solutions Inc. lifted its holdings in Danaher by 4.0% during the 4th quarter. Atria Wealth Solutions Inc. now owns 27,169 shares of the conglomerate’s stock worth $6,287,000 after buying an additional 1,034 shares during the last quarter. Finally, Syon Capital LLC lifted its holdings in Danaher by 54.7% during the 4th quarter. Syon Capital LLC now owns 6,960 shares of the conglomerate’s stock worth $1,610,000 after buying an additional 2,460 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,707 shares of company stock valued at $10,786,944. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.6 %

Shares of Danaher stock traded up $1.65 during trading hours on Friday, hitting $269.48. 1,464,013 shares of the company’s stock traded hands, compared to its average volume of 2,820,898. The stock has a 50 day simple moving average of $258.72 and a 200-day simple moving average of $254.44. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $199.60 billion, a PE ratio of 45.67, a PEG ratio of 4.62 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the company posted $2.05 earnings per share. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. Equities research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on DHR shares. The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Jefferies Financial Group began coverage on Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Bank of America boosted their target price on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada boosted their target price on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Barclays boosted their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $276.88.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.